Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Qiagen ( (QGEN) ) is now available.
The Netherlands Authority For the Financial Markets (AFM) has notified QIAGEN N.V. about a significant voting rights announcement involving Goldman Sachs Group Inc. The notification details various financial instruments and shares held by Goldman Sachs entities, indicating both real and potential voting rights and capital interests in QIAGEN. This disclosure could impact QIAGEN’s market perception and stakeholder relations, reflecting the extent of Goldman Sachs’ involvement in the company’s financial structure.
The most recent analyst rating on (QGEN) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a company operating in the biotechnology industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is listed on several stock exchanges including Frankfurt, NYSE, and SIX, and has a market focus on providing innovative solutions for the life sciences and healthcare sectors.
Average Trading Volume: 1,172,126
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.88B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.